These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 36946070)

  • 21. Amisulpride augmentation therapy improves cognitive performance and psychopathology in clozapine-resistant treatment-refractory schizophrenia: a 12-week randomized, double-blind, placebo-controlled trial.
    Zhu MH; Liu ZJ; Hu QY; Yang JY; Jin Y; Zhu N; Huang Y; Shi DH; Liu MJ; Tan HY; Zhao L; Lv QY; Yi ZH; Wu FC; Li ZZ
    Mil Med Res; 2022 Oct; 9(1):59. PubMed ID: 36253804
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sodium Benzoate, a D-Amino Acid Oxidase Inhibitor, Added to Clozapine for the Treatment of Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Trial.
    Lin CH; Lin CH; Chang YC; Huang YJ; Chen PW; Yang HT; Lane HY
    Biol Psychiatry; 2018 Sep; 84(6):422-432. PubMed ID: 29397899
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A 12-week, double-blind, placebo-controlled trial of donepezil adjunctive treatment to risperidone in chronic and stable schizophrenia.
    Akhondzadeh S; Gerami M; Noroozian M; Karamghadiri N; Ghoreishi A; Abbasi SH; Rezazadeh SA
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1810-5. PubMed ID: 18727948
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Add-On Pregnenolone with L-Theanine to Antipsychotic Therapy Relieves Negative and Anxiety Symptoms of Schizophrenia: An 8-Week, Randomized, Double-Blind, Placebo-Controlled Trial.
    Kardashev A; Ratner Y; Ritsner MS
    Clin Schizophr Relat Psychoses; 2018; 12(1):31-41. PubMed ID: 26218236
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness and tolerability of warm-supplementing kidney yang added to risperidone in improving cognitive impairment in patients with schizophrenia: An 8-week, multicenter, randomized, double-blind, placebo-controlled clinical trial.
    Chen ZH; Wang GH; Wang XP; Chen RY; Wang HL; Yang MH; Huo YX; Mei HB
    Curr Ther Res Clin Exp; 2008 Apr; 69(2):104-17. PubMed ID: 24692790
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dose reduction of risperidone and olanzapine can improve cognitive function and negative symptoms in stable schizophrenic patients: A single-blinded, 52-week, randomized controlled study.
    Zhou Y; Li G; Li D; Cui H; Ning Y
    J Psychopharmacol; 2018 May; 32(5):524-532. PubMed ID: 29493377
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Minocycline supplementation for treatment of negative symptoms in early-phase schizophrenia: a double blind, randomized, controlled trial.
    Liu F; Guo X; Wu R; Ou J; Zheng Y; Zhang B; Xie L; Zhang L; Yang L; Yang S; Yang J; Ruan Y; Zeng Y; Xu X; Zhao J
    Schizophr Res; 2014 Mar; 153(1-3):169-76. PubMed ID: 24503176
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Proof-of-concept randomized controlled trial of pregnenolone in schizophrenia.
    Marx CE; Lee J; Subramaniam M; Rapisarda A; Bautista DC; Chan E; Kilts JD; Buchanan RW; Wai EP; Verma S; Sim K; Hariram J; Jacob R; Keefe RS; Chong SA
    Psychopharmacology (Berl); 2014 Sep; 231(17):3647-62. PubMed ID: 25030803
    [TBL] [Abstract][Full Text] [Related]  

  • 29. L-carnosine as an adjuvant to fluvoxamine in treatment of obsessive compulsive disorder: A randomized double-blind study.
    Arabzadeh S; Shahhossenie M; Mesgarpour B; Rezaei F; Shalbafan MR; Ghiasi Z; Akhondzadeh S
    Hum Psychopharmacol; 2017 Jul; 32(4):. PubMed ID: 28485008
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic effect of adjunctive N-acetyl cysteine (NAC) on symptoms of chronic schizophrenia: A double-blind, randomized clinical trial.
    Sepehrmanesh Z; Heidary M; Akasheh N; Akbari H; Heidary M
    Prog Neuropsychopharmacol Biol Psychiatry; 2018 Mar; 82():289-296. PubMed ID: 29126981
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of adjunctive telmisartan treatment on psychopathology and cognition in patients with schizophrenia.
    Fan X; Song X; Zhao M; Jarskog LF; Natarajan R; Shukair N; Freudenreich O; Henderson DC; Goff DC
    Acta Psychiatr Scand; 2017 Nov; 136(5):465-472. PubMed ID: 28851055
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of buspirone, a serotonin1A partial agonist, on cognitive function in schizophrenia: a randomized, double-blind, placebo-controlled study.
    Sumiyoshi T; Park S; Jayathilake K; Roy A; Ertugrul A; Meltzer HY
    Schizophr Res; 2007 Sep; 95(1-3):158-68. PubMed ID: 17628435
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antidepressant Controlled Trial For Negative Symptoms In Schizophrenia (ACTIONS): a double-blind, placebo-controlled, randomised clinical trial.
    Barnes TR; Leeson VC; Paton C; Costelloe C; Simon J; Kiss N; Osborn D; Killaspy H; Craig TK; Lewis S; Keown P; Ismail S; Crawford M; Baldwin D; Lewis G; Geddes J; Kumar M; Pathak R; Taylor S
    Health Technol Assess; 2016 Apr; 20(29):1-46. PubMed ID: 27094189
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nanocurcumin as an Add-on to Antipsychotic Drugs for Treatment of Negative Symptoms in Patients With Chronic Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Study.
    Hosseininasab M; Zarghami M; Mazhari S; Salehifar E; Moosazadeh M; Fariborzifar A; Babaeirad S; Hendouei N
    J Clin Psychopharmacol; 2021 Jan/Feb 01; 41(1):25-30. PubMed ID: 33347019
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effects of pioglitazone adjuvant therapy on negative symptoms of patients with chronic schizophrenia: a double-blind and placebo-controlled trial.
    Iranpour N; Zandifar A; Farokhnia M; Goguol A; Yekehtaz H; Khodaie-Ardakani MR; Salehi B; Esalatmanesh S; Zeionoddini A; Mohammadinejad P; Zeinoddini A; Akhondzadeh S
    Hum Psychopharmacol; 2016 Mar; 31(2):103-12. PubMed ID: 26856695
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study.
    Lane HY; Chang YC; Liu YC; Chiu CC; Tsai GE
    Arch Gen Psychiatry; 2005 Nov; 62(11):1196-204. PubMed ID: 16275807
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vortioxetine as adjunctive therapy to risperidone for treatment of patients with chronic schizophrenia: A randomised, double-blind, placebo-controlled clinical trial.
    Moazen-Zadeh E; Bayanati S; Ziafat K; Rezaei F; Mesgarpour B; Akhondzadeh S
    J Psychopharmacol; 2020 May; 34(5):506-513. PubMed ID: 32122230
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor.
    Lane HY; Lin CH; Green MF; Hellemann G; Huang CC; Chen PW; Tun R; Chang YC; Tsai GE
    JAMA Psychiatry; 2013 Dec; 70(12):1267-75. PubMed ID: 24089054
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A double-blind, placebo-controlled trial of extract of Ginkgo biloba added to haloperidol in treatment-resistant patients with schizophrenia.
    Zhang XY; Zhou DF; Zhang PY; Wu GY; Su JM; Cao LY
    J Clin Psychiatry; 2001 Nov; 62(11):878-83. PubMed ID: 11775047
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-Dementia Drugs for Psychopathology and Cognitive Impairment in Schizophrenia: A Systematic Review and Meta-Analysis.
    Kishi T; Ikuta T; Oya K; Matsunaga S; Matsuda Y; Iwata N
    Int J Neuropsychopharmacol; 2018 Aug; 21(8):748-757. PubMed ID: 29762677
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.